Thromb Haemost 2005; 93(02): 381-382
DOI: 10.1055/s-0037-1616257
Case Report
Schattauer GmbH

Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage

Stefano Busani
1   Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena
,
Marco Marietta
2   Cattedra e Divisione di Ematologia, Università di Modena ee Reggio Emilia e Policlinico di Modena
,
Alberto Pasetto
1   Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena
,
Massimo Girardis
1   Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 04. August 2004

Accepted after revision 15. November 2004

Publikationsdatum:
14. Dezember 2017 (online)

 

 
  • References

  • 1 Dennis MS, Burn JP, Sandercock PA. et al Longterm survival after first-ever stroke: the Oxfordshire Community Stroke Project.. Stroke 1993; 24: 796-800.
  • 2 Qureshi I A, Thurim S, Broderick JP. et al Spontaneous intracerebral hemorrhage.. N Engl J Med 2001; 344: 1450-60.
  • 3 Broderick J, Adams HP, Barsan W. et al Intracerebral haemorrhage more than twice as common as subarachnoid haemorrhage.. J Neurosurg 1993; 78: 188-91.
  • 4 Brott T, Broderick J, Kothari R. et al Early hemorrhage growth in patients with intracerebral hemorrhage.. Stroke 1997; 28: 1-5.
  • 5 Kazui S, Naritomi H, Yamamoto H. et al Enlargement of spontaneous intracerebral haemorrhage: incidence and time course.. Stroke 1997; 28: 2370-5.
  • 6 Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage.. Stroke 2003; 34: 224-9.
  • 7 Hedner U. NovoSeven® as a universal haemostatic agent.. Blood Coagul Fibrinolysis 2000; 11: 107-11.
  • 8 Abshire T, Kenet G. Recombinant factor VIIa : review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.. J Thromb Haemost 2004; 2: 899-909.
  • 9 Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency.. Semin Thromb Hemost 2000; 26 (04) 401-5.
  • 10 Friederich PW, Wever PC, Briet E. et al Successful treatment with recombinant factor VIIa of therapy- 'resistant severe bleeding in a patient with acquired von Willebrand disease.. Am J Hematol 2001; 66: 292-94.
  • 11 Jeffers L, Chalasani N, Balart L. et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; Jul 123 (01) 118-26.
  • 12 Grounds M. Recombinant factor VIIa and its use in severe bleeding in surgery and trauma: a review.. Blood Reviews 2003; 17: S11-S21.
  • 13 Monroe DM, Hoffman M, Oliver JA. et al Platelet activity of high-dose factor VIIa is independent of tissue factor.. Br J Haematol. 1997; 99: 542-7.
  • 14 Poon MC, Demers C, Jobin F. et al Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.. Blood 1999; 94: 3951-3.
  • 15 Vidarsson B, Onudarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia.. Thromb Haemost 2000; 83: 634-5.
  • 16 Gerotziafas GT, Zervas C, Gavrielidis G. et al Effective haemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening haemorrhage.. Am J Hematol 2002; 69: 219-22.
  • 17 Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004; 41 S (01) 25-9.
  • 18 Mayer SA, Brun N, Broderick J. et al Recombinant factor VIIa for acute intracerebral haemorrhage. 5 th World Stroke Congress. June 23–26,2004. Vancouver B.C; Canada: Abstracts Book p.48